Is there a potential role for anti-tumor necrosis factor therapy in patients with human immunodeficiency virus?

Journal of Clinical and Aesthetic Dermatology

Volumn 2, Issue 4, 2009, Pages 29-35

  Emer, Jason J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; ETRETIN; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERFERON; ISONIAZID; LAMIVUDINE; LEFLUNOMIDE; LMP 420; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOXIFYLLINE; PLACEBO; PREDNISONE; RETINOID; RIBAVIRIN; SALAZOSULFAPYRIDINE; TAZAROTENE; THALIDOMIDE; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; APHTHOUS ULCER; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; OPPORTUNISTIC INFECTION; PHOTOTHERAPY; PREVALENCE; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; REITER SYNDROME; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCREENING; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

EID: 77954287525     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Rodahl E. Retroviruses and chronic arthritis. Possible significance of some recent observations. Scand J Rheumatol. 1989;18(6):335-339.
2. Duvic M, Johnson TM, Rapini RP, et al. Acquired immunodeficiency syndrome-associated psoriasis and Reiter's syndrome. Arch Dermatol. 1987;123(12):1622-1632.
3. Namazi MR. Paradoxical exacerbation of psoriasis in AIDS: proposed explanations including the potential roles of substance P and gram-negative bacteria. Autoimmunity. 2004;37(1):67-71.
4. Vittorio Luigi De Socio, G, Simonetti, S, Stagni, G. Clinical improvement of psoriasis in an AIDS patient effectively treated with combination antiretroviral therapy. Scand J Infect Dis. 2006;38(1):74-75.
5. Buchness MR. Treatment of skin diseases in HIV-infected patients. Dermatol Clin. 1995;13(1):231-238.
6. Duvic M, Crane MM, Conant M, et al. Zidovudine improves psoriasis in human immunodeficiency virus-positive males. Arch Dermatol. 1994;130(4):447-451.
7. Obuch ML, Maurer TA, Becker B, Berger TG. Psoriasis and human immunodeficiency virus infection. J Am Acad Dermatol. 1992;27(5 Pt 1):667-673.
8. Vano-Galvan S, Jaen P. Severe psoriasis due to cessation of antiretroviral therapy in a patient with human immunodeficiency virus. Isr Med Assoc J. 2008;10(7):557-558.
9. Mallon E, Bunker CB. HIV-associated psoriasis. AIDS Patient Care STDS. 2000;14(5):239-246.
10. Mamkin I, Mamkin A, Ramanan SV. HIV-associated psoriasis. Lancet Infect Dis. 2007;7(7):496.
11. Leal L, Ribera M, Daudén E. Psoriasis and HIV infection. Actas Dermosifiliogr. 2008;99(10):753-763.
12. Cuellar ML, Espinoza LR. Rheumatic manifestations of HIV-AIDS. Baillieres Best Pract Res Clin Rheumatol. 2000;14(3):579-593.
13. Aukrust P, Liabakk NB, Müller F, et al. Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection-correlations to clinical, immunologic, and virologic parameters. J Infect Dis. 1994;169(2):420-424.
14. Whalen C, Horsburgh CR, Hom D, et al. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med. 1995;151(1):129-135.
15. Duh EJ, Maury WJ, Folks TM, et al. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci U S A. 1989;86(15):5974-5978.
16. Dezube BJ, Lederman MM, Chapman B, et al. The effect of tenidap on cytokines, acute-phase proteins, and virus load in human immunodeficiency virus (HIV)-infected patients: correlation between plasma HIV-1 RNA and proinflammatory cytokine levels. J Infect Dis. 1997;176(3):807-810.
17. Valdez H, Lederman MM. Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev. 1997-1998:187-228.
18. Marriott JB, Cookson S, Carlin E, et al. A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines. AIDS Res Hum Retroviruses. 1997;13(18):1625-1631.
19. Wallis RS, Nsubuga P, Whalen C, et al. Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial. J Infect Dis. 1996;174(4):727-733.
20. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997;336(21):1487-1493.
21. Haraguchi S, Day NK, Kamchaisatian W, et al. LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells. AIDS Res Ther. 2006 Mar 31;3:8.
22. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20(4):757-790.
23. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2003;48(11):3013-3022.
24. Perlmutter A, Mittal A, Menter A. Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol. 2009;160(1):8-15. Epub 2008 Oct 22.
25. Doherty SD, Van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol. 2008;59(2):209-217. Epub 2008 May 15.
26. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850.
27. Walsh MJ, Vanags DM, Clouston AD, et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology. 2004;39(5):1230-1238.
28. Herbein G, O'Brien WA. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med. 2000;223(3):241-257.
29. Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol. 2008;159(6):1217-1228. Epub 2008 Sep 25.
30. Roux CH, Brocq O, Breuil V, et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford). 2006;45(10):1294-1297. Epub 2006 Apr 7.
31. Cooley L, Sasadeusz J. Clinical and virological aspects of hepatitis B co-infection in individuals infected with human immunodeficiency virus type-1. J Clin Virol. 2003;26(2): 185-193.
32. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol. 2008;48(2):353-367. Epub 2007 Dec 4.
33. Soto B, Sánchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997;26(1):1-5.
34. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol. 2006;21(9):1366-1371.
35. Zein, NN, Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005;42(3):315-322.
36. Meola T, Soter NA, Ostreicher R, et al. The safety of UVB phototherapy in patients with HIV infection. J Am Acad Dermatol. 1993;29(2 Pt 1):216-220.
37. Stern RS, Mills DK, Krell K, et al. HIV-positive patients differ from HIV-negative patients in indications for and type of UV therapy used. J Am Acad Dermatol. 1998;39(1):48-55.
38. Houpt KR, Beer JZ, Horn TD, et al. Ultraviolet therapy of HIV-infected individuals: a panel discussion. Semin Cutan Med Surg. 1997;16(3):241-245.
39. Beer JZ, Zmudzka BZ. UVB and PUVA therapies in HIV patients: are they safe? Photodermatol Photoimmunol Photomed. 1997;13(3):91-92.
40. Akaraphanth R, Lim HW. HIV, UV and immunosuppression. Photodermatol Photoimmunol Photomed. 1999;15(1): 28-31.
41. Kuwano Y, Watanabe R, Fujimoto M, et al. Treatment of HIV-associated eosinophilic pustular folliculitis with narrowband UVB. Int J Dermatol. 2006;45(10):1265-1267.
42. Morison WL. PUVA therapy is preferable to UVB phototherapy in the management of HIV-associated dermatoses. Photochem Photobiol. 1996;64(2):267-268.
43. Breuer-McHam J, Marshall G, Adu-Oppong A, et al. Alterations in HIV expression in AIDS patients with psoriasis or pruritus treated with phototherapy. J Am Acad Dermatol. 1999;40(1):48-60.
44. Calabrese LH, Lederman MM, Spritzler J, et al. Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantation. J Acquir Immune Defic Syndr. 2002;29(4):356-362.
45. Stock P, Roland M, Carlson L, et al. Solid organ transplantation in HIV-positive patients. Transplant Proc. 2001;33(7-8):3646-3648.
46. Tourne L, Durez P, Van Vooren JP, et al. Alleviation of HIV-associated psoriasis and psoriatic arthritis with cyclosporine. J Am Acad Dermatol. 1997;37(3 Pt 1):501-502.
47. Allen BR. Use of cyclosporin for psoriasis in HIV-positive patient. Lancet. 1992;339(8794):686.
48. Galeazzi M, Giannitti C, Manganelli S, et al. Treatment of rheumatic diseases in patients with HCV and HIV infection. Autoimmun Rev. 2008;8(2):100-103.
49. Maurer TA, Zackheim HS, Tuffanelli L, Berger TG. The use of methotrexate for treatment of psoriasis in patients with HIV infection. J Am Acad Dermatol. 1994;31(2 Pt 2):372-375.
50. Masson C, Chennebault JM, Leclech C. Is HIV infection contraindication to the use of methotrexate in psoriatic arthritis? J Rheumatol. 1995;22(11):2191.
51. Chernyshov P. Testing for HIV prior to methotrexate administration. Is it an obligatory procedure? Int J Dermatol. 2006;45(8):998-999.
52. Baker BS, Griffiths CE, Lambert S, et al. The effects of cyclosporine A on T lymphocyte and dendritic cell subpopulations in psoriasis. Transplant Proc. 1988;20(3 Suppl 4):72-77.
53. Kiyohara A, Takamori K, Niizuma N, Ogawa H. Successful treatment of severe recurrent Reiter's syndrome with cyclosporine. J Am Acad Dermatol. 1997;36(3 Pt 1): 482-483.
54. Blanche P. Acitretin and AIDS-related Reiter's disease. Clin Exp Rheumatol. 1999;17(1):105-106.
55. Buccheri L, Katchen BR, Karter AJ, Cohen SR. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol. 1997;133(6):711-715.
56. Ting PT, Koo JY. Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients. Int J Dermatol. 2006;45(6):689-692.
57. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis. 2004;63(Suppl 2):ii18-ii24.
58. Wachi K, Prasertsuntarasai T, Kishimoto M, Uramoto K. T-cell lymphopenia associated with infliximab and cyclophosphamide. Am J Med Sci. 2005;330(1):48-51.
59. Sha BE, Valdez H, Gelman RS, et al. Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2. AIDS Res Hum Retroviruses. 2002;18(9):661-665.
60. Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adj